ENVB
Enveric Biosciences Inc

14,065
Loading...
Loading...
News
all
press releases
Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...
Business Wire·7mo ago
News Placeholder
More News
News Placeholder
Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...
Business Wire·8mo ago
News Placeholder
Enveric Biosciences Announces Closing of $5 Million Public Offering
Enveric Biosciences, Inc. (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...
Business Wire·8mo ago
News Placeholder
Enveric Biosciences Announces Pricing of $5 Million Public Offering
Enveric Biosciences, Inc. (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...
Business Wire·8mo ago
News Placeholder
Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...
Business Wire·8mo ago
News Placeholder
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During J.P. Morgan Week 2025
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety...
Business Wire·9mo ago
News Placeholder
Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety...
Business Wire·10mo ago
News Placeholder
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior
Enveric Biosciences, Inc. (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogen small molecule therapeutics for the treatment of...
Business Wire·10mo ago
News Placeholder
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...
Business Wire·11mo ago
News Placeholder
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
Enveric Biosciences, Inc. (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogen small-molecule therapeutics for the treatment of...
Business Wire·11mo ago

Latest ENVB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.